Soumen Sadhu

Mr. Soumen Sadhu

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2020 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
SSSoumen Sadhu
Soumen Sadhu
RARupesh Agrawal
Rupesh Agrawal
RPRicha Pyare
Richa Pyare
CPCarlos Pavesio
Carlos Pavesio
MZManfred Zierhut
Manfred Zierhut
JBJyotirmay Biswas
Jyotirmay Biswas
After the outbreak of the disease COVID-19, it has reached pandemic proportions within a very short time. It is mainly transmitted human-to-human through direct contact with secretions from an infected person or through inhalation of droplets containing SARS-CoV-2. It is controversial whether the virus may be transmitted via tears. Exposed ocular surface can serve as a gateway in transmission and acquiring respiratory diseases. Considering the reported cases on healthcare workers indicating nosocomial transmission and the anatomical and physiological aspects it is perceived that ophthalmic healthcare professionals are at higher risk of contracting the virus by virtue of their job. In this narrative review we discuss current evidence around detection of SARS-CoV-2 in human tears and forms of transmissions reported to date. We also provide a comprehensive approach that may be implemented in an ophthalmic care facility to protect healthcare personnel, as well as patients, from contracting the virus.

1 January 2020 in Indian Journal Of Ophthalmology
Verified
Journal Article
Open access
PDF file
JBJyotirmay Biswas
Jyotirmay Biswas
SSSoumen Sadhu
Soumen Sadhu
PMParthopratim Dutta Majumder
Parthopratim Dutta Majumder
Purpose: To evaluate the effectiveness of biologic therapy in a cohort of patients with various types of refractory non-infectious uveitis and scleritis. Methods: A retrospective observational study on patients with non-infectious uveitis and scleritis who were not responding or had a high recurrence rate with the conventional treatment and had received biologic therapy. Results: We studied 18 patients (33 eyes) who received biological therapy between January 2017 and November 2019. The mean age was 30 ± 17 years and mean duration of uveitis was 36.8 months (range 1–120 months). Anterior uveitis (27.7%) was most commonly observed followed by scleritis, panuveitis, posterior, and intermediate uveitis. The most common etiology was Behçet's disease (4 patients, 22.2%) followed by juvenile idiopathic arthritis (3 patients, 16.6%), granulamotosis polyangitis, and idiopathic (2 patients each, 11.1%). Majority had trialled one or more immunosuppressive and were refractory in nature. Maximum patients had received adalimumab (61%) followed by infliximab (22%), rituximab (12%), and golimumab (6%). The median prednisolone dose was reduced from 30 mg (range 7.5–60 mg) to 5 mg (range 0–10 mg) after biological therapy (P = 0.002). Significant visual improvement was observed post biologic therapy (mean log mar VA 0.41 ± 0.62 improved to 0.23 ± 0.48 at the final visit, P = 0.008). Maximum number of patients (16 patients, 89%) responded well with biological therapy. Three patients developed recurrence and systemic complications were observed in two patients. Conclusion: Biologic therapy is effective in non-infectious refractory uveitis who were resistant to conventional therapy and may prolong disease recurrence.

1 September 2020 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
RSRanju Kharel Sitaula
Ranju Kharel Sitaula
AKAnadi Khatri
Anadi Khatri
MJMk Janani
Mk Janani
RMRajendra Mandage
Rajendra Mandage
SSSoumen Sadhu
Soumen Sadhu
JBJyotirmay Biswas
Jyotirmay Biswas
Importance: An observant Chinese doctor Li Wenliang became the first physician to alert the world about COVID-19. Being an ophthalmologist himself, he has put the additional onus on us. The fact that the ocular manifestation could be the first presenting feature of novel coronavirus pneumonia should not be ignored and the possibility of spread of SARS-CoV-2 through the ocular secretions cannot be ruled out. However, with breakthroughs still evolving about this disease, the calls are now louder for closer examination on the pathogenesis of conjunctivitis associated with it. Hence, we conducted a scoping review of all available literature till date to fill in the “potential” gaps in currently available knowledge on ocular manifestations of SARS-CoV-2 infection in an attempt to establish continuity in the “chain of information” from December 2019 till April 2020. We also summarize a possible hypothesis on much less understood and highly debated topics on regard to the etiopathogenesis of ocular involvement in SARS-CoV-2 based on either presence or absence of ACE2 receptor in the ocular surface. Methods: We conducted a scoping review search of published and unpublished SARS-CoV-2-related English language articles from December 2019 till mid of April 2020 from the online databases. The findings were summarized using text, tables, diagrams, and flowcharts. Results: The commonest ocular manifestation in SARS-CoV-2 infection is follicular conjunctivitis and has been the first manifestation of SARS-CoV-2 infection in 3 reported cases till date. The ocular surface inoculated with the SARS-CoV-2 leads to the facilitation of the virus to the respiratory system via the lacrimal passage. RT-PCR analysis of the ocular secretions has shown the presence of the SARS-CoV-2 nucleotides indicating the possibility of infection of ocular secretions. ACE2 receptors and its expression on the ocular mucosal surface are linked behind the etiopathogenesis of conjunctivitis. Conclusion: Conjunctivitis can be the presenting manifestation but may go unnoticed due to its mild nature. The ocular surface could serve as the entry gateway for the virus and ocular secretions could play a role in virus shed. The eye care personnel, as well as the general people, need to be more vigilant and adopt protective eye measures.

20 June 2025 in The Ocular Surface
Verified
Journal Article
Open access
SSSoumen Sadhu
Soumen Sadhu
IJIsabelle Jalbert
Isabelle Jalbert
LPLuz Palacios-Derflingher
Luz Palacios-Derflingher
AAAli Alghamdi
Ali Alghamdi
BGBlanka Golebiowski
Blanka Golebiowski
Fiona StapletonFiona Stapleton
Fiona Stapleton
To examine ocular surface epithelial immune cell (EIC) density and corneal nerve parameters between patients with dry eye disease (DED) compared to healthy controls with further comparisons between auto-immune - Sjӧgren Syndrome DED (SS-DED) and non-autoimmune - non-Sjӧgren Syndrome DED (NSS-DED) subtypes. A systematic review and meta-analysis following PRISMA guidelines (Prospero-CRD42023446763) were conducted including studies reporting corneal and conjunctival EIC density and/or corneal nerve parameters in DED and healthy controls using in vivo confocal microscopy. Electronic databases - PubMed, Embase, Scopus, Web of Science were searched from inception to March 2025. The meta-analysis included 24 studies (n = 1060 DED, n = 521 controls) reporting EIC density, 30 studies reporting nerve length (CNL; n = 1450 DED, n = 643 controls) and 20 studies reporting nerve density (CND; n = 919 DED, n = 462 controls) in the central cornea. Studies of other ocular surface locations were insufficient for meta-analysis. Higher central corneal EIC density was evident in DED compared to controls (MD: 57.9 cells/mm2; 95 % CI: 43.3, 72.5; p < 0.001), and in, SS-DED compared to NSS-DED (51.0 cells/mm2; 95 % CI: 12.0, 90.0; p = 0.01). DED had lower CNL (-4.0 mm/mm2; 95 % CI: 5.2, -2.7; p < 0.001) and CND (-7.2 nerves/mm2; 95 % CI: 10.3, -4.1; p < 0.001) compared to controls. No significant differences in nerve parameters were found between SS-DED and NSS-DED subtypes (CNL: 95 % CI: 3.0, 1.4, CND: 6.8, 4.8; p ≥ 0.46). DED involves substantial EIC infiltration and reduced corneal nerve parameters. SS-DED is distinguished by higher EIC density than NSS-DED, while no differences were observed in corneal nerve parameters.

9 September 2024 in Journal of Clinical Ophthalmology and Research
Verified
Journal Article
Open access
SSSoumen Sadhu
Soumen Sadhu
AIAsif Iqbal
Asif Iqbal
BSBhaskar Srinivasan
Bhaskar Srinivasan
PPPrema Padmanabhan
Prema Padmanabhan
We present a case of scleral lens surface crazing in a patient with keratoconus (KC) and chronic giant papillary conjunctivitis (GPC). A 45-year-old Asian male with known keratoconus (KC) and allergic eye disease in both eyes, who is an experienced scleral lens user, presented with a 3-month history of lens intolerance in the right eye. On examination, the right eye scleral lens showed extensive lens surface crazing with poor surface wettability. The upper tarsal conjunctiva showed conjunctival hypertrophy – active GPC. After allergy treatment and symptomatic improvement, the scleral lens was refitted after intensive cleaning and polishing with aluminum oxide. The lens surface showed significant improvement and good fitting characteristics, and the patient resumed lens wear. At 6 months of follow-up, the patient was asymptomatic, and the ocular condition was stable.

19 September 2026 in Annals of Medicine
Verified
Journal Article
Open access
SSSoumen Sadhu
Soumen Sadhu
Isabelle JalbertIsabelle Jalbert
Isabelle Jalbert
MWMengliang Wu
Mengliang Wu
FKFarshid Karimi
Farshid Karimi
AAAli Alghamdi
Ali Alghamdi
Fiona StapletonFiona Stapleton
Fiona Stapleton